KROS compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

KROSKeros Therapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

KROSKeros Therapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

KROS

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±25.5%▲+1.38%×0.05

May 14 '26±32.2%▼−8.34%×0.26

Q1 FY26±12.0%▼−14.96%×1.25

Nov 6 '25±16.3%▲+3.32%×0.20

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedKROS realized, solidLLY realized, hatchedOne scale, both sides: full bar = 33%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

KROSKeros Therapeutics, Inc.

9.58▲+1.38%

Mkt cap$185.5MRevenue$40MQ3 FY26Revenue$244MFY25

LLYELI Lilly & Co

1,373.45▲+0.64%

Regular sessionNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Regular sessionNov 6 '26

KROSKeros Therapeutics, Inc.

LLYELI Lilly & Co

9.58▲+1.38%

Price

1,373.45▲+0.64%

$185.5M

Mkt cap

$1.2T

Q3 FY26$40M

Revenue

$24.4BQ3 FY26

FY25$244M

Revenue

$65.2BFY25

KROS9.58▲+1.38%vsLLY1,373.45▲+0.64%Regular sessionNov 6 '26